GV, a venture capital investment firm, led a $17m Series A round in Pelage Pharmaceuticals, a clinical-stage regenerative medicine company. "Our scientific co-founders have uncovered a unique biological mechanism with the potential to reactivate hair growth in people with alopecia. We are pleased to announce that we have completed a first-in-human Phase 1 clinical trial that demonstrated seven days of topical dosing with PP405 was safe and well-tolerated, and showed statistically significant activation of hair follicle stem cells," Daniel Gil, Pelage Pharmaceuticals CEO.